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Effect of N-acetylcysteine for prevention of contrast nephropathy in
patients with moderate to severe renal insufficiency: A randomized trial
Fung JWH, Szeto CC, Chan WWM, et al. Am J Kidney Dis 2004;43:801–8.
Conclusion: Oral N-acetylcysteine (NAC) had no effect on prevention
of contrast nephropathy in patients with moderate-to-severe renal insuffi-
ciency undergoing coronary angiography or coronary interventions.
Summary: N-acetylcysteine is used as an antioxidant to prevent con-
trast nephropathy in patients undergoing contrast studies. The authors point
out conflicting results in randomized trials evaluating the efficacy of this
approach. They performed a prospective, open-label, randomized con-
trolled trial, in which 91 consecutive patients with a serum creatinine of
1.69–4.52 mg/dL who were undergoing coronary procedures were ran-
domly assigned to be administered either oral NAC, 400 mg 3 times daily
the day before and the day of the contrast procedure, or no drug (control
group). Serum creatinine was measured before and 48 hours after contrast
exposure. The primary end point was development of contrast nephropathy
defined as an increase in serum creatinine of 0.5 mg/dL or greater, or a
reduction in estimated glomerular filtration rate (GFR) of 25% or greater of
baseline value 48 hours after exposure to contrast.
There were 46 patients randomized to the NAC group and 46 controls.
The groups did not differ in baseline characteristics or mean volume of
contrast administered. Six patients (13.3%) in the control group and 8
patients (17.4%) in the NAC group developed contrast nephropathy (P 
.8). Serum creatinine levels increased from 2.27  0.54 to 2.45  0.65
mg/dL in the NAC group, and from 2.37 0.61 to 2.40 0.70 mg/dL in
the control group (P  .6). The increase in serum creatinine levels also did
not differ between the 2 groups (P  .7). Estimated GFR decreased from
30.3  8.4 to 28.1  8.4 mL/min (P  .01) in the NAC group and from
28.4  8.6 to 27.5  8.8 mL/min (P  .3) in the control group. The
decline in estimated GFR between the 2 groups was not significant (P .7).
Comment: In Table 2 of this article the authors summarize 15 previous
reports evaluating the effect of NAC on prevention of contrast nephropathy
in patients with renal insufficiency. Only 5 of the 15 reports indicate a benefit
in the use of NAC to prevent contrast nephropathy. The largest trial
evaluating NAC and the prevention of contrast nephropathy showed a
positive result, but the patients in that study had relatively mild renal
impairment. The potential benefit of NAC in preventing contrast nephrop-
athy in patients with more significant degrees of renal impairment remains
unproven.
Prevention of contrast-induced nephropathy with sodium bicarbonate
in a randomized controlled trial
Merten GJ, Burgess WP, Gray LP, et al. JAMA 2004; 291:2328–34.
Conclusion: Prior to contrast exposure, hydration with sodium bicar-
bonate is more effective than hydration with sodium chloride for prevention
of contrast-induced renal failure.
Summary: This was a prospective, single-center randomized trial of
119 patients with stable serum creatinine levels of at least 1.1 mg/dL.
Patients were randomized to receive a 154-mEq/L infusion of either
sodium chloride (n  59) or sodium bicarbonate (n  60) before and after
intravenous contrast administration (370 mg iodine/mL). Creatinine levels
were measured at baseline and at 1 and 2 days after contrast administration.
Either sodium bicarbonate or sodium chloride (154 mEq/L) was adminis-
tered as a bolus of 3 mL/kg per hour for 1 hour prior to contrast adminis-
tration. This was followed by an infusion of 1 mL/kg per hour for 6 hours
after completion of the procedure. Contrast-induced nephropathy was
defined as an increase of 25% or more in serum creatinine within 2 days of
contrast administration.
The 2 groups did not differ with respect to sex, prevalence of diabetes
mellitus, ethnicity, or contrast volume. Baseline serum creatinine was slightly
higher, but not statistically different, in patients receiving sodium bicarbon-
ate treatment than sodium chloride treatment (mean [SD], 1.71 [0.42]
mg/dL) and 1.89 [0.69] mg/dL; P .09). Contrast-induced nephropathy
occurred in 8 patients (13.6%) treated with sodium chloride but in only 1
(1.7%) of those receiving sodium bicarbonate (difference, 11.9%; 95%
confidence interval, 2.6%-21.2%; P  .02). A follow-up registry of 191
consecutive patients receiving prophylactic sodium bicarbonate and meeting
the same inclusion criteria as the study resulted in 3 cases of contrast-induced
nephropathy (1.6%; 95% confidence interval, 0%-3.4%).
Comment: Animal models suggest pretreatment with sodium bicar-
bonate may be more effective than sodium chloride in prevention of acute
ischemic renal failure. Renal failure from both ischemia and contrast is
postulated to occur at least partially from free-radical injury. The success of
sodium bicarbonate in reducing contrast-induced nephropathy is consistent
with the hypothesis that contrast injury is induced by free radicals. This study
contains persuasive data that sodium bicarbonate, rather than sodium chlo-
ride, should be used to provide pre- and postprocedure hydration in patients
undergoing contrast administration.
A Comparison of albumin and saline for fluid resuscitation in the
intensive care unit
The Safe Study Investigators. N Engl J Med 2004;350:2247–56.
Conclusion: In intensive care unit (ICU) patients, normal saline and
4% albumin for fluid resuscitation result in similar outcomes at 28 days.
Summary: The authors performed a multicenter randomized double-
blind trial to compare the effect of fluid resuscitation with albumin or saline
in a population of ICU patients. Patients 18 years or older who were
admitted to the ICU in 16 academic tertiary hospitals in Australia and New
Zealand were evaluated for participation in the study. Patients undergoing
cardiac surgery, liver transplantation, or treatment of burns were excluded.
Patients were randomly assigned to receive either normal saline or 4%
albumin for fluid resuscitation for the next 28 days. The primary outcome
measure was death from any cause within 28 days of randomization. Sec-
ondary outcome measures were the proportion of patients who had 1, 2, 3,
4, or 5 new organ failures; survival time during the first 28 days; duration of
mechanical ventilation; duration of renal replacement therapy; and duration
of ICU and hospital stay.
Of the 6997 study participants, 3497 were randomized to the albumin
group and 3500 to the saline group. The 2 groups had similar baseline
characteristics. There were 729 deaths in the saline group and 726 deaths in
the albumin-treated patients, P  .87. There were no differences between
the number of patients in each group with single or multiple organ failure,
P .85. There were also no significant differences between the groups in the
number of days spent in the ICU (6.5 6.6 in the albumin group and 6.2
6.2 in the saline group; P .44), total hospital days (15.3 9.6 and 15.6
9.6, respectively: P  .3), days of mechanical ventilation (4.5  6.1 and
4.3  5.7, respectively; P  .74), or days of renal replacement therapy
(0.5  2.3 and 0.4  2.0, respectively; P  .41).
During the first 3 study days patients receiving albumin had signifi-
cantly less fluid administered than those assigned to saline. The overall ratio
of volume of albumin to volume of saline administered during the first 4 days
was 1:1.4. After day 4 there were no difference in the 2 groups in volume of
study fluids administered.
Comment: Because it appears in the New England Journal of Medicine,
this article will likely be widely cited. The data, however, may not apply to
surgical patients undergoing massive resuscitation or to vascular surgical
patients. There is no breakdown of the number of patients undergoing
elective or urgent aortic surgery, or those who required massive amounts of
fluid resuscitation. The study should not be used to justify therapies in
specific subgroups of surgical patients, especially those who require massive
resuscitation.
Aneurysmal hypertension and its relationship to sac thrombus: A
semi-qualitative analysis by experimental fluid mechanics
Chaudhuri A, Ansdeoll E, Grass AG, et al. Eur J Vasc Endovasc Surg
2004;27:305–10.
Conclusion: Intraluminal thrombus in an aortic aneurysm may result
in localized areas of high intraluminal pressure.
Summary: Using a pulsatile flow model, the authors investigated the
effect of aneurysm thrombus and luminal diameter on pressure within the
abdominal aortic aneurysm model lumen and at the sac wall. A latex model
of an abdominal aortic aneurysm was incorporated into a pulsatile flow unit,
using blood pressures settings of 140/100 mm Hg and 130/90 mm Hg
(donated high and low settings, respectively). Pressures in the aneurysm sac
were measured in the absence of thrombus within the sac and were repeated
after a thrombus analog (gelatin) was introduced into the aneurysm model.
Using both pressure settings, luminal pressures and sac wall pressures were
compared with systemic pressure and with each other.
With the aneurysm sac devoid of thrombus, luminal and sac wall
pressures were identical to systemic pressure with high- and low-pressure
settings. With introduction of thrombus, pressure was transmitted in a
monophasic pulsatile fashion, with increases in systolic, diastolic, and mean
pressures at the sac wall compared with luminal pressure (166/142/151
mm Hg vs 164/136/145 mm Hg; P .001) with the high-pressure setting.
In the low-pressure setting readings were 157/133/141 mm Hg at the sac
wall for systolic, diastolic, and mean pressures versus 160/128/138 mm Hg
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